NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
In All, PortfolioCompany advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as Independent Director Cambridge, UK, Boston and Seattle – April 10th, 2019 – NodThera, a biotechnology company developing a new class…